The business model was R&D. They stated as much. When you see a company in the R&D phase on the OTC, run. It means that their main focus is to some day hit it big with a new product that they haven't yet invented.
To make matters worse, R&D almost always means heavy dilution for years. Drug companies often require decades. Here, FINRA refused to let XDSL RS so they eventually turned to toxic financing with no way to replenish their shares. They were bound to fail.
At this point, none of that matters. The company has changed it's focus from R&D to growth. That means that Anshu will bring products and services to market. They plan on having revenue immediately and eventually make a profit. As for R&D, he stated in his last pr that they plan on having other companies develop their products for a portion of their profits.